Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Equity (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Return on Equity for 4 consecutive years, with 0.51% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 100.0% to 0.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.51%, a 100.0% decrease, with the full-year FY2025 number at 0.64%, down 141.0% from a year prior.
  • Return on Equity was 0.51% for Q4 2025 at Phathom Pharmaceuticals, down from 0.66% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 2043.99% in Q3 2023 to a low of 0.51% in Q4 2025.
  • A 4-year average of 159.23% and a median of 1.61% in 2024 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 55bps in 2023, then crashed -204238bps in 2024.
  • Phathom Pharmaceuticals' Return on Equity stood at 3.9% in 2022, then increased by 14bps to 4.45% in 2023, then tumbled by -66bps to 1.52% in 2024, then tumbled by -66bps to 0.51% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Return on Equity are 0.51% (Q4 2025), 0.66% (Q3 2025), and 0.89% (Q2 2025).